Indoco Remedies Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/qzhzozm41iraxzcmfj114u7w.pdf

Key Takeaways


The Recovery: Green Shoots and Steep Climbs

Aditi Panandikar: "Coming out of such a period is not easy, but I am happy to share that while it is a steep road to recovery, there has been marginal improvement on many fronts."

Goa Plant-2: The Pivot Point

Aditi Panandikar: "Quite honestly, it is better to look at probably Q4 this year as a time for when we can start evaluating the Ophthal business to the US and its performance."

Domestic Formulations: A Tale of Two Data Sets

Aditi Panandikar: "This is the first time we saw both Cital and Cyclopam impacted together in one quarter at a primary level."

International Business: Exports and Semi-Regulated Markets


OTC Business and Warren Remedies


Balance Sheet and Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Goa Plant-2 remediation completionMost remediation work finishedBy August 2025
FDA re-audit invitationReach out to FDA to request inspectionFrom September 2025 onward
Master manufacturing full rolloutAll plants up and runningBy end of Q2 FY26 (Q3 FY26 from day one)
Europe supply recoveryOvercome supply challenges, return to regular supply levelsBounce back by Q3 FY26
US ophthalmic revenue evaluationStart evaluating ophthalmic business performance to the USQ4 FY26
Loan repayment~₹68 crores repaidRemaining 9 months of FY26
Incremental CAPEXNot more than ~₹50 croresFY26
R&D product filingsFile 4-5 productsFY26
MR productivityAdd at least ₹25,000 per man in incremental PHYBy end of FY26
Warren Remedies capital infusionInfuse capital to strengthen balance sheetComing 3 quarters
US FDA re-inspectionHope inspection occursCalendar year 2025

Key Metrics

MetricQ1 FY26
Consolidated net revenue₹429.1 cr, vs ₹424.3 cr same quarter last year and ₹383.9 cr immediately preceding quarter
Standalone net revenue₹383.8 cr, vs ₹394.2 cr same quarter last year and ₹341.1 cr immediately preceding quarter, 12.5% growth on Q4 FY25
Consolidated EBITDA margin4.1%, vs 11.3% same quarter last year; preceding quarter was negative
Standalone EBITDA margin3.9%, vs 13.1% same quarter last year; preceding quarter was 1%
Domestic formulation revenue₹202.8 cr, vs ₹200.2 cr same quarter last year
International formulation revenue₹139.3 cr, vs ₹157.1 cr same quarter last year
US business revenue₹28.3 cr, vs ₹48.7 cr same quarter last year
Europe revenue₹63.5 cr, vs ₹75.4 cr same quarter last year
Emerging markets revenue₹44.3 cr, vs ₹29.8 cr same quarter last year
API business revenue₹36.6 cr, vs ₹31.2 cr same quarter last year
OTC revenue₹31.6 cr, growth of more than 46% over immediate preceding quarter
R&D expenses₹21.6 cr, expected to be maintained at 5%–5.5% of sales
Consolidated net debt₹950 cr, short-term ₹350 cr and long-term ₹600 cr as of 30th June 2025, reduced by ₹21 cr from March 2025
Remediation cost~₹4 cr per quarter
Incremental CAPEX expected for FY26~₹50 cr